01:03 , Apr 21, 2009 |  BC Extra  |  Clinical News

Pharmasset off after stopping clevudine trials

Pharmasset Inc. (NASDAQ:VRUS) fell $0.92 (10%) to $8.33 on Monday after ending two Phase III trials of clevudine to treat HBV infection following serious adverse events among those using the drug in South Korea, where...
07:00 , Jun 18, 2007 |  BC Week In Review  |  Clinical News

Racivir: Phase II data

In a Phase II trial, 600 mg of oral Racivir reduced viral loads by a mean of 0.7 log10 (80%) in responders with the M184V mutation and <3 thymidine analog mutations. VRUS is developing Racivir...
07:00 , May 15, 2006 |  BioCentury  |  Finance

Ebb & Flow

After three weeks of downtime on the IPO front, two U.S. biotechs got out last week. It seems that investors were using the break to sharpen their shears. The good news is that Novacea (NOVC)...
07:00 , Jul 4, 2005 |  BC Week In Review  |  Company News

Pharmasset, Bukwang Pharm. Co. Ltd. deal

Pharmasset Inc. , Tucker, Ga.   Bukwang Pharm. Co. Ltd. , Seoul, South Korea   Bukwang granted Pharmasset exclusive rights to develop and commercialize clevudine to treat HBV in the Americas, Europe, the Caribbean and...
01:04 , Jun 28, 2005 |  BC Extra  |  Company News

Pharmasset in-licenses clevudine

Bukwang Pharm (Seoul, South Korea) granted Pharmasset (Tucker, Ga.) exclusive rights to develop and commercialize clevudine to treat HBV in the Americas, Europe, the Caribbean and Israel. Bukwang received an option to Pharmasset's Racivir to...
08:00 , Feb 21, 2005 |  BioCentury  |  Product Development

HIV pipeline

HIV pipeline Company Product Target Status Pfizer UK-427,857 CC chemokine receptor 5 (CCR5) Ph III Achillion Elvucitabine Reverse transcriptase Ph II GlaxoSmithKline/Ono GW873140 (ONO-4128) CCR5 Ph II GlaxoSmithKline/ Vertex VX-385 Protease Ph II Incyte/Pharmasset Reverset...
08:00 , Feb 21, 2005 |  BioCentury  |  Product Development

New focus on HIV pipeline

The emergence of a case of AIDS in New York that is resistant to 17 of the 20 marketed drugs is a reminder that the four classes of existing drugs only address three targets on...
08:00 , Nov 15, 2004 |  BC Week In Review  |  Clinical News

Racivir: Started Phase II

Pharmasset began the placebo-controlled, international Phase II RCV-201 trial in 60 patients who have been receiving Epivir for 60 days and have viral load of >=2,000 copies/ml. The study will be blinded for up to...
08:00 , Nov 10, 2004 |  BC Extra  |  Clinical News

Pharmasset starts Racivir Phase II

Pharmasset (Tucker, Ga.) began the placebo-controlled, international Phase II RCV-201 trial of Racivir in 60 HIV patients. The trial, which is enrolling patients who have been receiving Epivir for 60 days and have viral load...
08:00 , Nov 1, 2004 |  BioCentury  |  Product Development

Poly-nating the HCV space

The gaggle of companies developing oral polymerase inhibitors to treat HCV just got a little bigger, as Roche has signed with Pharmasset Inc. to develop PSI 6130, an oral nucleoside polymerase inhibitor in late preclinical...